With the purchase of Gemzar® from Eli Lilly and Company, which was signed on 2 October 2024 and closed on 13 December 2024, the CHEPLAPHARM Group is once again expanding its existing portfolio in the oncology sector. The transaction includes the transfer of worldwide commercial rights (except South Korea).
CHEPLAPHARM is the global market leader in the acquisition of established originator products from research-based pharmaceutical companies. With the purchase of Gemzar®, CHEPLAPHARM is acquiring a proven chemotherapeutic agent for the treatment of various types of cancer: non-small cell lung cancer, urothelial, biliary tract, pancreatic, ovarian, cervical and breast cancer. The active substance gemcitabine is included in the WHO Model Lists of Essential Medicines.
‘We are delighted that we were able to successfully close the Gemzar® transaction in just over two months after signing in October, continuing the good and trustful cooperation with Lilly following the acquisition of the Zyprexa® portfolio last year,’ says Edeltraud Lafer, CEO of CHEPLAPHARM.
Gemzar® is a well-established branded medicine that further strengthens CHEPLAPHARM's existing oncology portfolio. With brands such as Vesanoid®, Tarceva®, Xeloda®, Myocet®, Paraplatin® and Taxol® the company already has a broad and patient-orientated product portfolio for the treatment of various types of cancer.
The transaction includes intellectual property and product registrations.